Skip to main content
. 2008 May 1;5:56. doi: 10.1186/1743-422X-5-56

Figure 1.

Figure 1

Design and biochemical characterization of BFFI. A. Schematic diagram of BFFI. BFFI is composed of the CCR5mAb RO-Ab0630, with two covalently attached T-2635 fusion inhibitors via {G(Q)4}3 linkers. The peptide sequences for the linker and T-2635 are shown. B. SDS-PAGE of BFFI and CCR5mAb. The lanes contain the following samples: Sample Buffer (lane 2, 5); MW Marker (lane 1); BFFI (lane 3); CCR5mAb (lane 4); reduced BFFI (lane 6); reduced CCR5mAb (lane 7).